This conversation focuses on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy?
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.
This conversation centers around two thoughts about the EASL Congress 2024 from Michelle Long.one on network value and the other on the reat benefit that comes from reviewing abstracts in advance.
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
